Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Apr:66:103343.
doi: 10.1016/j.ebiom.2021.103343. Epub 2021 Apr 16.

Shigella conjugate vaccine efficacy trial in controlled human model and potential immune correlates of protection

Rubhana Raqib  1 , Malabi Venkatesan  2
Affiliations
Comment

Shigella conjugate vaccine efficacy trial in controlled human model and potential immune correlates of protection

Rubhana Raqib et al. EBioMedicine. 2021 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare no conflicts of interest.

Comment on

References

    1. Khalil IA, Troeger C, Blacker BF, Rao PC, Brown A, Atherly DE, Brewer TG, Engmann CM, Houpt ER, Kang G, Kotloff KL, Levine MM, Luby SP, MacLennan CA, Pan WK, Pavlinac PB, Platts-Mills JA, Qadri F, Riddle MS, Ryan ET, Shoultz DA, Steele AD, Walson JL, Sanders JW, Mokdad AH, Murray CJL, Hay SI, Reiner RC., Jr. Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990-2016. Lancet Infect Dis. 2018 Nov;18(11):1229–1240. - PMC - PubMed
    1. Talaat KR, Alaimo C, Martin P, Bourgeois AL, Dreyer AM, Kaminski RW, Porter CK, Chakraborty S, Clarkson KA, Brubaker J, Elwood D, Frölich R, DeNearing B, Weerts HP, Feijoo B, Halpern J, Sack D, Riddle MS, and Fonck VG. Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection. E Bio Med. (in press) - PMC - PubMed
    1. Clarkson KA, Talaat KR, Alaimo C, Martin P, Bourgeois AL, Dreyer A, Porter CK, Chakraborty S, Brubaker J, Elwood D, Frölich R, DeNearing B, Weerts HP, Feijoo B, Halpern J, Sack D, Riddle MS, Fonck VG and Kaminski RW. Immune response characterization in a human challenge study with a Shigella flexneri 2a Bioconjugate Vaccine. E Bio Med. (in press) - PMC - PubMed
    1. MacLennan CA, Riddle MS, Chen WH, Talaat KR, Jain V, Bourgeois AL, Frenck R, Kotloff K, Porter CK. Consensus report on shigella controlled human infection model: clinical endpoints. Clin Infect Dis. 2019 Dec 9;69(Suppl 8):S591–S595. - PMC - PubMed
    1. Porter CK, Lynen A, Riddle MS, Talaat K, Sack D, Gutiérrez RL, McKenzie R, DeNearing B, Feijoo B, Kaminski RW, Taylor DN, Kirkpatrick BD, Bourgeois AL. Clinical endpoints in the controlled human challenge model for Shigella: a call for standardization and the development of a disease severity score. PLoS One. 2018 Mar 28;13(3) - PMC - PubMed

LinkOut - more resources